Live Breaking News & Updates on Nasdaq Ymab|Page 3
Stay updated with breaking news from Nasdaq ymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has received a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. […] ....
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 3,140,000 shares, a growth of 52.4% from the July 31st total of 2,060,000 shares. Based on an average daily volume of 244,800 shares, the days-to-cover ratio […] ....
Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) had its target price cut by Morgan Stanley from $7.00 to $5.00 in a report published on Monday morning, MarketBeat Ratings reports. They currently have an underweight rating on the stock. Several other research analysts also recently commented on the company. Bank of America lifted their target price on […] ....
HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ Q3 2023 earnings at ($0.18) EPS, Q4 2023 earnings at ($0.19) EPS […] ....
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target decreased by stock analysts at Morgan Stanley from $7.00 to $5.00 in a research note issued on Monday, FlyOnTheWall reports. Morgan Stanley’s target price indicates a potential downside of 9.91% from the company’s previous close. YMAB has been the subject of a number of […] ....